Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid (NAPOLEON-2 study)

Yasunori Kawaguchi, Kohei Hayashi, Mototsugu Shimokawa, Taiga Otsuka, Junichi Nakazawa, Hozumi Shimokawa, Yudai Shinohara, Futa Koga, Noriko Oza, Hisanobu Oda, Shigeyuki Takeshita, Shiho Arima, Shuji Arita, Kazuo Nishikawa, Satoshi Otsu, Hiroki Taguchi, Kenichi Jikuya, Tatsunori Sakai, Yujiro Ueda, Takahiro Sakae, Norimasa Araki, Hironori Sawase, Yasushi Ide, Machiko Kawahira, Kenta Nio, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi

Therapeutic Advances in Medical Oncology

Published online on April 21, 2026

Abstract

Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard second- or later-line regimen for unresectable or recurrent pancreatic cancer (urPC). However, validated prognostic biomarkers are lacking.Objectives:In this study, ...